It can take up to $2 million and several months to complete Phase I of a clinical trial. On top of that 3% of adverse reactions during Phase I are categorized as severe.

This is why we are introducing Pharma-sci: a way to predict drug dosage and potential side effects for different demographics using pharmacodynamics to understand the mechanisms of a drug.

BenchSci can maximize its impact through this new risk management tool by giving its clients access to a comprehensive, easy-to-use tool on pharmacodynamics. Using this tool researchers can successfully implement pharmacodynamics into their pre-clinical research, allowing them to understand how drug mechanisms are affected by different demographics and create more accurate starting points for dosages during Phase 1 clinical trials.

Want to Learn More? ⬇️

The Problem

Our Solution

Current Solutions

Opportunity For BenchSci

Plan For Implementation

Meet our Team!

Anna Heck

Anna Heck is a 16-year-old interested in remote monitoring using sensors and synthetic biology.

Molly Jin

Molly Jin is a 17-year old interested in using protein modelling, bioinformatics and public health.

Pari Vansjalia

Pari Vansjalia is a ****16 year old student interested in polypharmacy and rural healthcare.